this article has been archived; content may be out of date.
Customer is King: producing products that patients want
|24th July 2014
Harry Crook, from HA Crook Pharmacy Limited, talks about the importance of providing a patient-centric experience. Pharma companies should be producing products that patients want, because the patient is the most important thing. If, as a company, you don’t do it right then they go somewhere else!
In the booklet 'Customer Experience: The Essential Guide for Pharma', we mention that the customer isn't as concerned about the pharmaceutical company as they are about the drugs they make. Harry Crook agrees:
Pharmaceutical companies provide people like Harry Crook with a tool - the drug. It’s then their responsibility to give the patient a truly patient-centric experience with that product. At Blue Latitude Health, we know what it means to look at the patient journey from the patient's perspective. Behaviour changes from pre-diagnosis, diagnosis, treatment and recovery to the management of their condition. This affects their choices, decisions, and attitudes towards a service or product; as laid out in our Patient Information Journey poster.
Read more about human-centred design and customer engagement in our second issue of Perspective magazine.
Precision paediatrics: Treating patients with CAR-T
|9th July 2019
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality
What does it mean to be an agile organisation
|27th June 2019
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market.
Battling breast cancer with precision medicine (Part 2)
|20th June 2019
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives his side of the story and explains how industry can help oncologists treat more patients with targeted therapies.